Literature DB >> 29197216

Early Cognitive, Structural, and Microstructural Changes in Presymptomatic C9orf72 Carriers Younger Than 40 Years.

Anne Bertrand1,2,3,4, Junhao Wen2,5, Daisy Rinaldi1,6, Marion Houot7, Sabrina Sayah5, Agnès Camuzat5, Clémence Fournier5, Sabrina Fontanella2,5, Alexandre Routier2,5, Philippe Couratier8,9, Florence Pasquier10,11, Marie-Odile Habert12,13, Didier Hannequin14,15, Olivier Martinaud14,15, Paola Caroppo5,16, Richard Levy1,6,7, Bruno Dubois1,6,7, Alexis Brice1, Stanley Durrleman2,5, Olivier Colliot1,2,17, Isabelle Le Ber1,6,7.   

Abstract

Importance: Presymptomatic carriers of chromosome 9 open reading frame 72 (C9orf72) mutation, the most frequent genetic cause of frontotemporal lobar degeneration and amyotrophic lateral sclerosis, represent the optimal target population for the development of disease-modifying drugs. Preclinical biomarkers are needed to monitor the effect of therapeutic interventions in this population.
Objectives: To assess the occurrence of cognitive, structural, and microstructural changes in presymptomatic C9orf72 carriers. Design, Setting, and Participants: The PREV-DEMALS study is a prospective, multicenter, observational study of first-degree relatives of individuals carrying the C9orf72 mutation. Eighty-four participants entered the study between October 2015 and April 2017; 80 (95%) were included in cross-sectional analyses of baseline data. All participants underwent neuropsychological testing and magnetic resonance imaging; 63 (79%) underwent diffusion tensor magnetic resonance imaging. Gray matter volumes and diffusion tensor imaging metrics were calculated within regions of interest. Anatomical and microstructural differences between individuals who carried the C9orf72 mutation (C9+) and those who did not carry the C9orf72 mutation (C9-) were assessed using linear mixed-effects models. Data were analyzed from October 2015 to April 2017. Main Outcomes and Measures: Differences in neuropsychological scores, gray matter volume, and white matter integrity between C9+ and C9- individuals.
Results: Of the 80 included participants, there were 41 C9+ individuals (24 [59%] female; mean [SD] age, 39.8 [11.1] years) and 39 C9- individuals (24 [62%] female; mean [SD] age, 45.2 [13.9] years). Compared with C9- individuals, C9+ individuals had lower mean (SD) praxis scores (163.4 [6.1] vs 165.3 [5.9]; P = .01) and intransitive gesture scores (34.9 [1.6] vs 35.7 [1.5]; P = .004), atrophy in 8 cortical regions of interest and in the right thalamus, and white matter alterations in 8 tracts. When restricting the analyses to participants younger than 40 years, compared with C9- individuals, C9+ individuals had lower praxis scores and intransitive gesture scores, atrophy in 4 cortical regions of interest and in the right thalamus, and white matter alterations in 2 tracts. Conclusions and Relevance: Cognitive, structural, and microstructural alterations are detectable in young C9+ individuals. Early and subtle praxis alterations, underpinned by focal atrophy of the left supramarginal gyrus, may represent an early and nonevolving phenotype related to neurodevelopmental effects of C9orf72 mutation. White matter alterations reflect the future phenotype of frontotemporal lobar degeneration/amyotrophic lateral sclerosis, while atrophy appears more diffuse. Our results contribute to a better understanding of the preclinical phase of C9orf72 disease and of the respective contribution of magnetic resonance biomarkers. Trial Registration: clinicaltrials.gov Identifier: NCT02590276.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29197216      PMCID: PMC5838615          DOI: 10.1001/jamaneurol.2017.4266

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  41 in total

1.  Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.

Authors:  Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

2.  Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers.

Authors:  Renée Walhout; Ruben Schmidt; Henk-Jan Westeneng; Esther Verstraete; Meinie Seelen; Wouter van Rheenen; Marcel A de Reus; Michael A van Es; Jeroen Hendrikse; Jan H Veldink; Martijn P van den Heuvel; Leonard H van den Berg
Journal:  Neurology       Date:  2015-10-23       Impact factor: 9.910

3.  The B-matrix must be rotated when correcting for subject motion in DTI data.

Authors:  Alexander Leemans; Derek K Jones
Journal:  Magn Reson Med       Date:  2009-06       Impact factor: 4.668

4.  Disease progression in C9orf72 mutation carriers.

Authors:  Mary K Floeter; Bryan J Traynor; Jennifer Farren; Laura E Braun; Michael Tierney; Edythe A Wiggs; Tianxia Wu
Journal:  Neurology       Date:  2017-06-14       Impact factor: 9.910

5.  Correction for geometric distortion in echo planar images from B0 field variations.

Authors:  P Jezzard; R S Balaban
Journal:  Magn Reson Med       Date:  1995-07       Impact factor: 4.668

6.  Frontotemporal dementia associated with the C9ORF72 mutation: a unique clinical profile.

Authors:  Emma Devenney; Michael Hornberger; Muireann Irish; Eneida Mioshi; James Burrell; Rachel Tan; Matthew C Kiernan; John R Hodges
Journal:  JAMA Neurol       Date:  2014-03       Impact factor: 18.302

7.  Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images.

Authors:  J L Whitwell; B F Boeve; S D Weigand; M L Senjem; J L Gunter; M C Baker; M DeJesus-Hernandez; D S Knopman; Z K Wszolek; R C Petersen; R Rademakers; C R Jack; K A Josephs
Journal:  Eur J Neurol       Date:  2015-02-12       Impact factor: 6.089

8.  Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia.

Authors:  Sarat C Vatsavayai; Soo Jin Yoon; Raquel C Gardner; Tania F Gendron; Jose Norberto S Vargas; Andrew Trujillo; Mochtar Pribadi; Joanna J Phillips; Stephanie E Gaus; John D Hixson; Paul A Garcia; Gil D Rabinovici; Giovanni Coppola; Daniel H Geschwind; Leonard Petrucelli; Bruce L Miller; William W Seeley
Journal:  Brain       Date:  2016-10-22       Impact factor: 13.501

9.  C9ORF72 hexanucleotide expansions of 20-22 repeats are associated with frontotemporal deterioration.

Authors:  Estrella Gómez-Tortosa; Jesús Gallego; Rosa Guerrero-López; Alberto Marcos; Eulogio Gil-Neciga; María José Sainz; Asunción Díaz; Emilio Franco-Macías; María José Trujillo-Tiebas; Carmen Ayuso; Julián Pérez-Pérez
Journal:  Neurology       Date:  2013-01-02       Impact factor: 9.910

10.  RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention.

Authors:  Christopher J Donnelly; Ping-Wu Zhang; Jacqueline T Pham; Aaron R Haeusler; Aaron R Heusler; Nipun A Mistry; Svetlana Vidensky; Elizabeth L Daley; Erin M Poth; Benjamin Hoover; Daniel M Fines; Nicholas Maragakis; Pentti J Tienari; Leonard Petrucelli; Bryan J Traynor; Jiou Wang; Frank Rigo; C Frank Bennett; Seth Blackshaw; Rita Sattler; Jeffrey D Rothstein
Journal:  Neuron       Date:  2013-10-16       Impact factor: 17.173

View more
  34 in total

Review 1.  Defining pre-symptomatic amyotrophic lateral sclerosis.

Authors:  Michael Benatar; Martin R Turner; Joanne Wuu
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-03-20       Impact factor: 4.092

Review 2.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

Review 3.  Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Suvi Häkkinen; Stephanie A Chu; Suzee E Lee
Journal:  Neurobiol Dis       Date:  2020-09-02       Impact factor: 5.996

Review 4.  FTD spectrum: Neuroimaging across the FTD spectrum.

Authors:  Jennifer L Whitwell
Journal:  Prog Mol Biol Transl Sci       Date:  2019-06-18       Impact factor: 3.622

5.  Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers.

Authors:  Qin Chen; Bradley F Boeve; Christopher G Schwarz; Robert Reid; Nirubol Tosakulwong; Timothy G Lesnick; Jessica Bove; Patrick Brannelly; Danielle Brushaber; Giovanni Coppola; Christina Dheel; Bradford C Dickerson; Susan Dickinson; Kelley Faber; Julie Fields; Jamie Fong; Tatiana Foroud; Leah Forsberg; Ralitza H Gavrilova; Debra Gearhart; Nupur Ghoshal; Jill Goldman; Jonathan Graff-Radford; Neill R Graff-Radford; Murray Grossman; Dana Haley; Hilary W Heuer; Ging-Yuek R Hsiung; Edward Huey; David J Irwin; Clifford R Jack; David T Jones; Lynne Jones; Anna M Karydas; David S Knopman; John Kornak; Joel Kramer; Walter Kremers; Walter A Kukull; Maria Lapid; Diane Lucente; Codrin Lungu; Ian R A Mackenzie; Masood Manoochehri; Scott McGinnis; Bruce L Miller; Rodney Pearlman; Leonard Petrucelli; Madeline Potter; Rosa Rademakers; Eliana M Ramos; Katherine P Rankin; Katya Rascovsky; Pheth Sengdy; Leslie Shaw; Jeremy Syrjanen; Nadine Tatton; Joanne Taylor; Arthur W Toga; John Trojanowski; Sandra Weintraub; Bonnie Wong; Adam L Boxer; Howie Rosen; Zbigniew Wszolek; Kejal Kantarci
Journal:  Neurobiol Aging       Date:  2019-08-15       Impact factor: 4.673

Review 6.  Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis.

Authors:  Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan
Journal:  CNS Drugs       Date:  2021-05-15       Impact factor: 5.749

7.  Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study.

Authors:  Jackie M Poos; Lucy L Russell; Georgia Peakman; Martina Bocchetta; Caroline V Greaves; Lize C Jiskoot; Emma L van der Ende; Harro Seelaar; Janne M Papma; Esther van den Berg; Yolande A L Pijnenburg; Barbara Borroni; Raquel Sanchez-Valle; Fermin Moreno; Robert Laforce; Caroline Graff; Matthias Synofzik; Daniela Galimberti; James B Rowe; Mario Masellis; Carmela Tartaglia; Elizabeth Finger; Rik Vandenberghe; Alexandre de Medonça; Fabrizio Tagliavini; Chris R Butler; Isabel Santana; Isabelle Le Ber; Alex Gerhard; Simon Ducharme; Johannes Levin; Adrian Danek; Markus Otto; Sandro Sorbi; Florence Pasquier; John C van Swieten; Jonathan D Rohrer
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-13

Review 8.  Cognitive dysfunction in amyotrophic lateral sclerosis: can we predict it?

Authors:  Fabiola De Marchi; Claudia Carrarini; Antonio De Martino; Luca Diamanti; Antonio Fasano; Antonino Lupica; Mirella Russo; Simone Salemme; Edoardo Gioele Spinelli; Alessandro Bombaci
Journal:  Neurol Sci       Date:  2021-03-27       Impact factor: 3.307

9.  Synaptic density in carriers of C9orf72 mutations: a [11 C]UCB-J PET study.

Authors:  Maura Malpetti; Negin Holland; P Simon Jones; Rong Ye; Thomas E Cope; Tim D Fryer; Young T Hong; George Savulich; Timothy Rittman; Luca Passamonti; Elijah Mak; Franklin I Aigbirhio; John T O'Brien; James B Rowe
Journal:  Ann Clin Transl Neurol       Date:  2021-06-16       Impact factor: 5.430

10.  MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia.

Authors:  Ziqiang Lin; Eugene Kim; Mohi Ahmed; Gang Han; Camilla Simmons; Yushi Redhead; Jack Bartlett; Luis Emiliano Pena Altamira; Isobel Callaghan; Matthew A White; Nisha Singh; Stephen Sawiak; Tara Spires-Jones; Anthony C Vernon; Michael P Coleman; Jeremy Green; Christopher Henstridge; Jeffrey S Davies; Diana Cash; Jemeen Sreedharan
Journal:  Brain Commun       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.